ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Walgreens Boots Alliance, Inc. Investors to Inquire About Securities Class Action Investigation - WBA ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Lawsuit Against Walgreens - The Department of Justice (DOJ) has filed a lawsuit against Walgreens, alleging the company dispensed millions of unlawful prescriptions from August 2012 to the present [1] - The DOJ claims Walgreens knowingly filled prescriptions that lacked legitimate medical purpose, were invalid, or not issued in the usual course of professional practice [1] - The lawsuit aims to hold Walgreens accountable for failing to meet its obligations in dispensing dangerous opioids and other drugs [1] Allegations of Unlawful Practices - Walgreens pharmacists allegedly filled millions of prescriptions with clear red flags indicating they were highly likely to be unlawful [2] - The company systematically pressured pharmacists to fill prescriptions, including controlled substances, without confirming their validity [2] - These practices allegedly allowed millions of opioid pills and other controlled substances to flow illegally out of Walgreens stores [2] Consequences of Alleged Actions - Some Walgreens patients reportedly died of overdoses shortly after receiving invalid prescriptions filled at Walgreens [2] Legal Proceedings - The 300-page lawsuit was filed in the U.S. District Court in Chicago [3]

To say that pharmacy retailer Walgreens Boots Alliance (WBA 3.19%) has been struggling would be a massive understatement. It's coming off a horrendous year in 2024, when its share price crashed by 64%. The stock has been trading around levels it hasn't been at in decades as investors are concerned about the company's future.However, contrarian investors may hope that this can be a good turnaround play. That assumes that Walgreens can drastically cut costs and improve its financials as it focuses on profitab ...

The top executive at Walgreens lamented the loss of sales from putting items like toothpaste behind lock and key to crack down on rampant shoplifting that has plagued pharmacy chains around the country.“When you lock things up…you don’t sell as many of them. We’ve kind of proven that pretty conclusively,” Tim Wentworth, CEO of Walgreens Boots Alliance, told investors during a recent earnings call.He went on to say that grappling with retail theft was akin to a “hand-to-hand combat battle” and called the ant ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Shares of Walgreens Boots Alliance (WBA 2.86%) fell sharply last year as a combination of declining vaccine demand, headwinds on consumer discretionary spending, and misguided acquisitions led to a series of dismal earnings reports from the company.As a result, Walgreens was forced to cut its dividend, took a multibillion-dollar impairment charge, and lost its place in the Dow Jones Industrial Average (^DJI 0.52%). According to data from S&P Global Market Intelligence, the stock fell 64% over the course of ...

The Walgreens store at 3646 N. Broadway in Chicago on Nov. 28, 2024. The Wall Street Journal ... [+] reported that Walgreens Boots Alliance is considering selling the company to a private equity firm. (Terrence Antonio James/Chicago Tribune/Tribune News Service via Getty Images)TNSWalgreens stock surged 27% on Friday, Jan 10, after the company reported upbeat Q1 (fiscal ends in August) results. It reported revenue of $39.5 billion and adjusted earnings of $0.51 per share, compared to the consensus estimates ...

Core Viewpoint - Walgreens Boots Alliance has shown signs of recovery in early 2025 after a significant decline in 2024, with better-than-expected fiscal Q1 2025 results indicating ongoing turnaround efforts [1] Financial Performance - Revenue increased by 7.5% year over year to $39.5 billion, surpassing analyst expectations, while adjusted EPS fell 29% to $0.51, exceeding the consensus of $0.37 [2] - U.S. retail pharmacy sales rose 6.6% year over year, with same-store sales up 8.5%, although comparable retail sales decreased by 4.6% due to a slower cold and flu season [3] - Adjusted operating income for the U.S. pharmacy business dropped 36.4% year over year to $441 million, with gross margins declining from 18.8% to 17% [4] Store Closures and Strategy - The company closed 67 locations in the quarter and plans to close approximately 450 more by the end of 2025, which is expected to improve profitability in the long run [5][9] - Initial inventory management and merchandising efforts have begun, although these have negatively impacted retail sales in the quarter [5] International Performance - International sales grew by 6.5% year over year, with Boots UK sales up 4.6%, and adjusted operating income increased by 16.1% to $168 million [6] Healthcare Segment - Revenue from the U.S. healthcare segment rose 12% year over year to $2.17 billion, with significant growth in partnerships such as VillageMD and specialty pharmacy Shields [7] Debt and Cash Flow - The company ended the quarter with $8.1 billion in debt and $1.2 billion in cash, generating negative free cash flow of $424 million due to seasonal inventory buildups [8] Future Outlook - Walgreens maintains its fiscal full-year guidance for adjusted EPS of $1.40 to $1.80, indicating confidence in its recovery strategy [8] - The company’s contracts for 2025 are expected to alleviate some reimbursement pressures, which is a critical area to monitor [10] Valuation - Walgreens trades at a forward P/E ratio of 7.7 and an enterprise value to EBITDA multiple of 5, suggesting the stock is undervalued [12] Competitive Landscape - The company faces competition from Walmart and Amazon, which are capitalizing on Walgreens' store closures by offering free same-day prescription deliveries [13]

Core Viewpoint - Walgreens Boots Alliance shares surged 27.5% on January 10, 2024, but this is insufficient to recover from a 64% decline in the previous year [1] Financial Performance - In the fiscal first quarter ending November 30, 2024, adjusted earnings were $0.51 per share, exceeding Wall Street's consensus estimate of $0.40 per share, although still less than half of previous earnings [4] - Walgreens provided a forward-looking guidance range of $1.40 to $1.80 per share for fiscal 2025, compared to the analyst expectation of $1.58 per share [5] - U.S. retail pharmacy sales increased by 6.6% year over year, but adjusted operating income from U.S. retail operations fell to 1.3% of sales, down from 4% two years ago [10] Analyst Insights - Evercore analyst raised the price target for Walgreens from $9 to $12 per share, reflecting a positive adjustment but still close to the stock's closing price of $11.75 [6] Industry Challenges - The retail pharmacy industry faces significant pressure from vertically integrated pharmacy benefits managers (PBMs) that control 79% of prescription drug claims, which Walgreens lacks [7][8] - The rise of low-cost providers like Mark Cuban's Cost Plus Drugs has made dispensing generic drugs a low-margin business, impacting Walgreens' profitability [9] Operational Losses - Walgreens' U.S. healthcare segment reported a loss of $325 million in the fiscal first quarter, contributing to an overall operating loss of $245 million for the period [11] - The high dividend yield of over 8% is attractive, but without profits, there is a risk of future dividend cuts [12]